Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wix.Com Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Wix.Com Ltd trades at $50.3 (market cap $2.10B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19× Wix.Com Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | WIX | |
|---|---|---|
Market Cap | $39.89B | $2.10B |
Sector | Health | Technology |
52-Week High | $491.22 | $184.24 |
52-Week Low | $278.09 | $40.43 |
Enterprise Value | $38.15B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wix trades at $50.14, up 1.83% today, with a bearish technical signal despite recent earnings beats in Q3 and Q4 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -1.97%. Recent news includes partnerships with Elavon and Microsoft, but multiple law firms are investigating potential securities fraud following a 27% stock drop in May 2026.
Analyst consensus is bullish with a $83.13 price target, but risks include ongoing fraud investigations, volatile cash flows, and negative shareholder equity. The stock faces headwinds from competitive pressures and execution risks despite strong revenue growth and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
